Abstract:Introduction There is a growing number of referrals to urologists for oncofertility inquiries and concerns. Contemporary oncologic agents and their effect on fertility outcomes remain poorly understood. No study to date has evaluated the most common chemotherapeutic, immunologic, and targeted therapies seen by urologists and assessed their respective impacts on fertility. Objective We evaluated the effect of common contemporary chemotherapy, immunotherapy, and targeted therapy regimens on fertility outcomes. Methods We performed a single institutional review of all oncologic drugs taken by patients in the hematology/oncology clinic over the past five years (April, 2018- April, 2023). Agents were defined as contemporary if approval was received by the Food and Drug Administration 2006 or later. A review of the literature was conducted using PubMed to evaluate the effects on fertility for each drug. The MESH terms included agents [common name] OR [brand name] AND [sperm] OR [fertility] OR [infertility] OR [pregnancy] OR [birth] OR [reproductive] OR [reproduction] OR [ovarian] OR [testicular]. Search results for each agent were classified as "fertility impacted" or "fertility not impacted". Studies were excluded if the primary aim or. secondary aim included fertility outcomes as a direct impact of chemotherapy, immunotherapy, or target therapy. Results We identified 75 patients who were treated with 28 unique contemporary oncologic agents. At least half of these agents demonstrated fertility inquiries in multiple patients referred. Agents with consultation >5 occasions included brentuximab (9), pembroluzimab (8), blinotumomab (8), pazopanib (6), and nivolumab (6). A total of 2,629 studies resulted from our search of which 56 studies met inclusion criteria determined by two independently blinded reviewers. Impact on fertility was defined as impaired spermatogenesis, reduced total sperm count/function, hypogonadism, impaired folliculogenesis or decreased ovarian reserve/function. Eight studies were conducted on animal models. Thirty-two studies reported an impact on fertility. Agents mostly commonly demonstrating fertility concerns included Melphalan (14), Ipilimumab (4), Pembrolizumab (3), Olaparib (2), and Trametinib (2). The most common drug classes affecting fertility outcomes included alkylating agents and immune checkpoint inhibitors. The majority of agents had only one study assessing fertility outcomes. At least a third of agents had literature to both support and oppose their impact on fertility. Conclusions Contemporary oncologic agents demonstrate significant variability in their impact on fertility. There is limited consensus on fertility outcomes amongst common oncologic agents referred to urologists for fertility workup. Evidence supporting negative fertility impacts is more commonly demonstrated among alkylating agents and immune checkpoint inhibitors. However, the available literature regarding the fertility impact of contemporary oncologic agents is limited and varied, reinforcing the need for provider familiarity and future research. Disclosure No.

Fertility and reproductive concerns related to the new generation of cancer drugs and the clinical implication for young individuals undergoing treatments for solid tumors

Pediatric Cancer Immunotherapy and Potential for Impact on Fertility: A Need for Evidence-Based Guidance

The Effects of Cancer Immunotherapy on Fertility: Focus on Hematological Malignancies

Oncofertility as an Essential Part of Comprehensive Cancer Treatment in Patients of Reproductive Age, Adolescents and Children

(380) The Effect of Contemporary Oncologic Agents on Fertility Outcomes: A Review of the Literature

Oncofertility care for children, adolescents, and young adults at risk for treatment-related fertility loss

Oncofertility: What can we do from bench to bedside?

(305) Contemporary Therapies in Oncofertility: Identifying the Common Consults

An update on oncofertility in prepubertal females

Current practices in oncofertility counseling: updated evidence on fertility preservation and post-treatment pregnancies in young women affected by early breast cancer

Issues with Fertility in Young Women with Breast Cancer

Current state of fertility preservation for adolescent and young adult patients with gynecological cancer

Review of fertility preservation issues for young women with breast cancer

What reproductive follow-up for adolescent and young women after cancer? A review

Current Status of Fertility Preservation in Pediatric Oncology Patients

[New strategies for fertility preservation in young women with cancer]

"Looking at future cancer survivors, give them a roadmap": addressing fertility and family-building topics in post-treatment cancer survivorship care

Cancer Therapy, Gonadal Function, and Fertility Preservation: Narrative Review

An approach to fertility preservation in prepubertal and postpubertal females: A critical review of current literature

Pharmacogenomic studies of fertility outcomes in pediatric cancer survivors – A systematic review

Alkylating agents-induced gonadotoxicity in prepubertal males: Insights on the clinical and preclinical front